Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

Abstract

BACKGROUND: Natalizumab (NAT) is an established disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, its use involves complex decision-making, often leading to initial use of lower efficacy therapies. Recently, the first biosimilar NAT was approved, enabling competitive pricing. This study assessed the societal implications of initiating NAT in various scenarios through a cost-consequence analysis.

METHODS: A 10-year Markov model based on the Expanded Disability Status Scale (EDSS) was employed, with 11 health states, annual cycles, and half-cycle correction. The cohort had an initial age of 36 years and 70% females. NAT was compared to common initial therapies (glatiramer acetate, teriflunomide, dimethyl fumarate, and fingolimod). Scenarios included continuous use, early (after 1 year), and delayed (5 years) switch to NAT. Baseline characteristics and probabilities for clinical and economic outcomes were derived from clinical trial data, published literature, and other available sources.

RESULTS: Continuous NAT use resulted in the highest time spent on low EDSS levels, fewer relapses, reduced years of life lost due to disability, and a higher employment rate over a 10-year period. Switching to NAT after 1 year yielded outcomes similar to continuous NAT use. Despite higher DMT costs, disease management costs, including indirect costs and non-DMT direct medical costs, were lower in continuous use and early switch to NAT. Late switching resulted in outcomes most comparable to continuous use of the initial DMT.

CONCLUSION: Continuous and early switch to NAT resulted in better clinical outcomes and lower societal economic burden compared to delayed NAT initiation, indicating potential long-term cost savings.

Details

Original languageEnglish
Article number153
Number of pages1
JournalJournal of neurology
Volume272
Issue number2
Publication statusPublished - 17 Jan 2025
Peer-reviewedYes

External IDs

ORCID /0000-0001-8799-8202/work/176343726
unpaywall 10.1007/s00415-024-12723-4
Scopus 85216059618

Keywords

Keywords

  • Adult, Computer Simulation, Cost-Benefit Analysis, Female, Humans, Immunologic Factors/economics, Male, Markov Chains, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Natalizumab/economics, Time Factors, Multiple sclerosis, Markov model, Cost–consequence, Health economics, Economic evaluation, Treatment strategies